Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — September 2024

Biotek-snakken — September 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
100 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #8

    Der er næsten ingen volumen, så pt. har de helt store aktionærer valgt ikke at sælge ud ..

    1 Reply Last reply
    0
    • A Offline
      A Offline
      Aps_invest
      wrote on sidst redigeret af
      #9

      Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System
      I dag kl. 10:35 ∙ MFN
      Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that Connected Cardiovascular Care Associates (C3), the first U.S. cardiology practice dedicated exclusively to the digital monitoring of cardiac conditions, has placed a four-unit order of the CADScor System.

      1 Reply Last reply
      0
      • A Offline
        A Offline
        Aps_invest
        wrote on sidst redigeret af
        #10

        The CADScor System will complement C3's suite of digital wearable devices, including smartwatches, digital blood pressure monitors, and weight scales, solidifying the practice's commitment to innovative, patient-centric care. This approach allows for continuous monitoring and early intervention, crucial for managing conditions such as heart blockages, rhythm problems, weakened heart function, and vascular issues like leg blockages or vein problems.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #11

          ARCTIC BIOSCIENCE: ABG kutter kursmålet til NOK 17 (54), gjentar kjøp. Det veritable kuttet forklarer de med bytte av analytiker. (den har nok neppe vært fulgt opp særlig siden siste analyse.. )

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Rasbom
            wrote on sidst redigeret af
            #12

            Exitnu jeg brugt også dagen fald til at øge min position i IBT. Så vil tiden vise om det var en god beslutning. Vi bliver lidt klogere i morgen når der er Live præsentation

            1 Reply Last reply
            0
            • exitnuE Offline
              exitnuE Offline
              exitnu
              wrote on sidst redigeret af
              #13

              @Rasbom - okay 🙂 I dag købte jeg i intervallet fra kurs 32 ned til næsten kurs 22, og fik derved forøget min IBT-position med næsten 128%. Solgte herefter ca. 33% af min totale position omkring kurs ca. 37,5. Den solgte position havde et GAK på præcis kurs 27,4. Spændende hvad morgendagen bringer 🙂

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #14

                Blot bare, så ingen misforståelser: jeg har pt. stort tab på min IBT-position ... 🙂

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #15

                  3 Monster Biotech Stocks to Buy Before 2025 https://proinvestor.com/investornyt/1208380/3-monster-biotech-stocks-to-buy-before-2025

                  1 Reply Last reply
                  0
                  • F Offline
                    F Offline
                    Fandel
                    wrote on sidst redigeret af
                    #16

                    Godmorgen...

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #17

                      Godmorgen 🙂

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #18

                        Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops https://proinvestor.com/investornyt/1208915/ascendis-pharma-reaches-150-mln-royalty-funding-agreement-with-royalty-pharma-stock-drops

                        1 Reply Last reply
                        0
                        • exitnuE Offline
                          exitnuE Offline
                          exitnu
                          wrote on sidst redigeret af
                          #19

                          IBT: SEB BEDÖMER ODDS SOM POSITIVA FÖR GODKÄNNANDE AV IBP-9414

                          I dag kl. 08:08 ∙ Nyhetsbyrån Direkt

                          STOCKHOLM (Nyhetsbyrån Direkt) SEB bedömer att oddsen för ett godkännande av läkemedelskandidaten IBP-9414 är positiva.

                          1 Reply Last reply
                          0
                          • R Offline
                            R Offline
                            Rasbom
                            wrote on sidst redigeret af
                            #20

                            Har du event et link til den exitnu den ville være interessant at læse fuldt ud

                            1 Reply Last reply
                            0
                            • exitnuE Offline
                              exitnuE Offline
                              exitnu
                              wrote on sidst redigeret af
                              #21

                              Ascelia Pharma: Secures full support from the completed Rights Issue

                              The preliminary result is 100% support and a gross proceed of SEK 105m. This outcome also adds future support from warrants due in spring 2025, adding SEK 30m gross (based on today’s share price).

                              Just a moment...

                              favicon

                              (www.redeye.se)

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #22

                                @Rasbom - Nej desværre, men læst mere her: https://proinvestor.com/boards/122067/

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #23

                                  "In summary, Ascilia has secured financial stability to progress with the most essential value drivers over the next 12 months. Our Base Case is SEK 12 (Bull SEK 31 and Bear SEK 2.3)."

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #24

                                    N8bio To Cut About 49% Of Jobs, Suspend Glioblastoma Development Program https://proinvestor.com/investornyt/1209492/in8bio-to-cut-about-49-of-jobs-suspend-glioblastoma-development-program

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      Bjæssing09
                                      wrote on sidst redigeret af
                                      #25

                                      Meget tyder på iflg. chatten på discord, at Saniona er meget tæt på en godkendelse af deres fedmemiddel Tesofensine i Mexico, sp hvem tør være ude af den aktie 🙂

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        Bjæssing09
                                        wrote on sidst redigeret af
                                        #26

                                        Saniona med fut i bagdelen i dag forud for godkendelsen i Mexico......

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          Bjæssing09
                                          wrote on sidst redigeret af
                                          #27

                                          Kursen skal jo ganges med 3 på en godkendelse, så folk vil nok gerne med i dag.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper